1 Min Read
* Checkpoint Therapeutics initiates phase 1 study of anti-PD-L1 antibody CK-301
* Checkpoint Therapeutics Inc - look forward to providing clinical updates on phase 1 study in first half of 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.